Search

Author/Creator Rouse, Tomas

1. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. (February 2021)

Authors:
Bruce, Ian N; Nami, Alireza; Schwetje, Erik; Pierson, M Edward; Rouse, Tomas; Chia, Yen Lin; Kuruvilla, Denison; Abreu, Gabriel; Tummala, Raj; Lindholm, Catharina
Journal:
Lancet
Issue:
Volume 3:Number 2(2021)
Page Start:
e101
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. (21st May 2022)

Authors:
Chia, Yen Lin; Tummala, Raj; Mai, Tu H.; Rouse, Tomas; Streicher, Katie; White, Wendy I.; Morand, Eric F.; Furie, Richard A.
Journal:
Journal of clinical pharmacology
Issue:
Volume 62:Number 9(2022)
Page Start:
1094
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗